Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Vertex Pharmaceuticals beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday.Please watch the video at Investors.com - How To Buy ...

US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s ...

There are questions about what to do before Trump takes office – how to change names and genders on identification cards, ...

Sufferers now living an extra eight years on average following a Daily Express campaign to help people get lifesaving ...